Drugs / mRNA-1645-eODGT8

Trials 1

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06694753 Dec 2025 → Dec 2026 expected HIV infectious disease International AIDS Vaccine Initiative Active not recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as mRNA-1645-eODGT8 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06694753 ↗
Modality Messenger RNA (mRNA) “eOD-GT8 60mer will be delivered using an mRNA lipid nanoparticle (LNP) platform.” NCT06694753 ↗
Route Intramuscular “To be administered by intramuscular (IM) injection at doses of 10 or 30 mcg.” NCT06694753 ↗